Numerous lawsuits seek to hold Merck liable for failing to adequately warn consumers about the increased risk of blood clots associated with the use of the NuvaRing contraceptive device, which is manufactured by Merck’s Organon subsidiary (Schering-Plough acquired Organon in 2007; Schering-Plough merged with Merck in 2009). Plaintiffs claim to have suffered a variety of serious side effects from using NuvaRing, including pulmonary embolism, deep vein thrombosis, stroke, and heart attack. In February 2014, Merck paid $100 million to settle all federal and state claims without admitting any liability or wrongdoing.